Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorHenan Cancer Hospital
About this trial
This study is a randomized, open-label, multi-center investigator-initiated clinical trial. Patients who meet the inclusion criteria receive the treatment plan stipulated in the protocol. A Bayesian design is used to explore the efficacy and safety of teprotumumab combined with pulse chemotherapy in the treatment of advanced second-line extensive-stage small cell lung cancer.
Eligibility criteria
Qualifiers
1.Age ≥18 years old, both male and female are acceptable.
always has not received the immune therapy,
Previously received immunotherapy, with the number of treatment lines ≥2 and the immunotherapy being effective(immunotherapy PFS > 3 months, withdrawal time > 3 months)
never used anlotinib,
Disqualifiers
1.Those who are allergic to toripalimab or etoposide or have metabolic disorders;
2.With known the special ripley sheet resistance, etoposide contraindication;
3.Other circumstances that the researcher assessed as unsuitable for participation in this clinical study.
Trial design
Treatments tested in this trial
- Toripalimab; Etoposide
Treatment groups
130 Participants
are divided into 5 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov